26319 Beta 2 Glycoprotein 1, IgA

​​Anti-Phospholipid Antibodies, Antiphospholipid Antibodies, Antiphospholipid syndrome, APS, anti-B₂-GP1 antibodies, Beta 2 glycoprotein, Beta-2 glycoprotein, Beta-2 GP1, systemic lupus erythematosus, SLE

​This semi-quantitative test panel detects IgA antibodies to Beta-2 Glycoprotein to aid in the diagnosis of primary Antiphospholipid Syndrome (APS) and those secondary to systemic lupus erythematosus (SLE) or SLE-disorders.

​Separate serum from cells within 2 hours of collection.

​The B2IGA test utilizes multiplex flow immunoassay, a methodology that greatly resembles traditional EIA, but permits simultaneous detection and identification of many antibodies in a single tube.

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the venous and/or arterial thrombosis, thrombocytopenia, recurrent fetal loss, and moderate-to-high titers of antiphospholipid (aPL) antibodies, lupus anticoagulant (LA), anti-Cardiolipin (aCL) antibodies, and anti-B₂-GP1 antibodies.  A definitive diagnosis of APS requires the presence of at least one clinical manifestation and one​ positive laboratory result.  Due to the heterogeneous nature of aPL antibodies, combined measurements of ACL and B₂GP1 antibodies may provide better sensitivity than either assay alone.